Phase 4 IOP Signals Associated With ILUVIEN®

• Status: Unknown status
• Trial end date: 2020-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alimera Sciences
• Treatments: Fluocinolone Acetonide

Criteria

Inclusion Criteria:

• Patients who are eligible for treatment with ILUVIEN based on the Prescribing Information.

Exclusion Criteria:

• Patients who are unable to understand and sign the Informed Consent Form.